Shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) have earned an average rating of “Reduce” from the ten analysts that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation and nine have issued a hold recommendation on the company.
Separately, The Goldman Sachs Group began coverage on Bayer Aktiengesellschaft in a research report on Thursday, May 30th. They set a “neutral” rating for the company.
View Our Latest Research Report on BAYRY
Bayer Aktiengesellschaft Price Performance
Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) last released its quarterly earnings data on Tuesday, May 14th. The company reported $0.77 earnings per share for the quarter. Bayer Aktiengesellschaft had a negative net margin of 6.70% and a positive return on equity of 17.57%. The business had revenue of $14.95 billion for the quarter. On average, analysts anticipate that Bayer Aktiengesellschaft will post 1.35 EPS for the current fiscal year.
Bayer Aktiengesellschaft Company Profile
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.
See Also
- Five stocks we like better than Bayer Aktiengesellschaft
- What is a Stock Market Index and How Do You Use Them?
- Survey: Top 175 Fittest Retirement Locations in America
- Top Stocks Investing in 5G Technology
- Kimberly-Clark Stock Dips and a Buying Opportunity Emerges
- Why is the Ex-Dividend Date Significant to Investors?
- Leading Gold Stock Shines With Q2 2024 Earnings Release
Receive News & Ratings for Bayer Aktiengesellschaft Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer Aktiengesellschaft and related companies with MarketBeat.com's FREE daily email newsletter.